Todos os posts

Breve revisão | Evolução do manejo da sedação na unidade de terapia intensiva.

4 Ago, 2022 | 14:10h

Evolution of sedation management in the intensive care unit (ICU) – Intensive Care Medicine (se o acesso a este link for pago, tente este)

 

Comentário no Twitter

Evolution of sedation practices in #ICU, from keeping critical patients deeply sedated to let them rest to wake them up on minimal sedation, assuring comfort but promoting liberation from MV & recovery/survivorship
📎 https://t.co/IlpSkJEfnC

PS free to read link tomorrow #FOAMcc pic.twitter.com/GFVxsEibdH

— Intensive Care Medicine (@yourICM) July 29, 2022

 

---

Estudo randomizado | Segurança e eficácia da tirzepatida como adição à medicação anti-hiperglicêmia oral única em pacientes com diabetes tipo 2 no Japão.

4 Ago, 2022 | 14:09h

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Ver também (nota: a dose de dulaglutida usada neste estudo foi provavelmente subótima): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem

— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022

 

---

Estudo pré-pós intervenção | Avaliação das calorias compradas após indicação calórica na etiquetas de alimentos preparados em uma grande rede de supermercados.

4 Ago, 2022 | 14:06h

Assessment of Calories Purchased After Calorie Labeling of Prepared Foods in a Large Supermarket Chain – JAMA Internal Medicine (gratuito por tempo limitado)

Comentário: Calorie Labels Don’t Deter Most Grocery Shoppers — Adding labels to prepared foods only yielded small decreases in calories purchased – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

New @JAMAInternalMed study of 173 supermarkets across 5 states shows that #calorie #labeling results in ⬇️ in calories purchased from prepared bakery and deli items, but not for prepared entrees/sideshttps://t.co/afCWAvhQ2L

— Rishi Wadhera, MD MPP (@rkwadhera) August 1, 2022

 

---

M-A | Eficácia de uma dieta restritiva na síndrome do intestino irritável.

4 Ago, 2022 | 14:05h

Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis – Korean Journal of Gastroenterology

Comentário: Gluten-Free, Low FODMAP Diets Beneficial for IBS Symptoms – HCPLive

Conteúdos relacionados:

Diet or medication in primary care patients with IBS: the DOMINO study – a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute – Gut

AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review – Gastroenterology

RCT: Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet and the gluten-free diet.

10 mistakes in dietary management of irritable bowel syndrome and how to avoid them.

Supplement: Irritable bowel syndrome and related conditions.

RCT: FODMAPs, but not gluten, elicit modest symptoms of irritable bowel syndrome.

RCT: Among patients with diarrhea-predominant irritable bowel syndrome, a low FODMAP diet achieved earlier symptomatic improvements in stool frequency and excessive wind.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Guidelines for the treatment of irritable bowel syndrome

ACG Clinical Guideline: Management of irritable bowel syndrome

M-A: Efficacy of a low-FODMAP diet in adult irritable bowel syndrome

 

---

Estudo de coorte retrospectiva | Sequência de gencitabina e docetaxel intravesical parece ser efetiva para câncer de bexiga de alto risco sem invasão muscular em pacientes que não utilizaram BCG intravesical.

4 Ago, 2022 | 14:03h

Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin–Naïve High-Risk Nonmuscle-Invasive Bladder Cancer – Journal of Urology

Comentário: Intravesical chemotherapy combination provides effective treatment alternative for high-risk non-muscle invasive bladder cancer – Wolters Kluwer

 

---

Revisão | Tratamento da descompensação hepática na doença hepática avançada (comprometimento renal, insuficiência hepática, insuficiência suprarrenal e complicações cardiopulmonares).

4 Ago, 2022 | 14:02h

Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications) – Clinical Drug Investigation

 

---

Revisão | Doenças que podem se apresentar de forma semelhante à dor ciática.

4 Ago, 2022 | 14:01h

Sciatica Mimics – emDocs

 

---

Revisão | Manifestações cutâneas da lesão renal aguda.

4 Ago, 2022 | 14:00h

Cutaneous manifestations of acute kidney injury – Clinical Kidney Journal

 

---

Revisão | Tratamento da lesão renal aguda em pacientes oncológicos.

4 Ago, 2022 | 13:59h

Treatment of acute kidney injury in cancer patients – Clinical Kidney Journal

Conteúdos relacionados:

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron

Acute Kidney Injury in Critically Ill Patients with Cancer – Clinical Journal of the American Society of Nephrology

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents – Kidney Research and Clinical Practice

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer – Kidney International

 

---

Estudo randomizado | Em pacientes sob risco de deficiência antitrombínica após cirurgia cardíaca, a suplementação antitrombínica pré-operatória não resultou em desfechos melhores.

4 Ago, 2022 | 13:58h

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antithrombin Supplementation in Patients at Risk for Antithrombin Deficiency After Cardiac Surgery – Anesthesia & Analgesia (link para o resumo – $ para o texto completo)

 

---